The estimated Net Worth of Anthony Hunt is at least $67.3 millió dollars as of 14 June 2024. Mr. Hunt owns over 2,000 units of Repligen stock worth over $23,686,382 and over the last 11 years he sold RGEN stock worth over $39,226,703. In addition, he makes $4,424,560 as President, Chief Executive Officer és Director at Repligen.
Anthony has made over 29 trades of the Repligen stock since 2016, according to the Form 4 filled with the SEC. Most recently he bought 2,000 units of RGEN stock worth $248,160 on 14 June 2024.
The largest trade he's ever made was exercising 50,039 units of Repligen stock on 21 May 2020 worth over $1,205,940. On average, Anthony trades about 8,690 units every 47 days since 2014. As of 14 June 2024 he still owns at least 165,177 units of Repligen stock.
You can see the complete history of Mr. Hunt stock trades at the bottom of the page.
Anthony John Hunt serves as President, Chief Executive Officer, Director of the Company. He joined Repligen in May 2014 as Chief Operating Officer, overseeing commercial and manufacturing operations. Before coming to Repligen, Mr. Hunt was President of Bioproduction at Life Technologies, a global life sciences company which was acquired by Thermo Fisher Scientific in 2014. He joined Life Technologies in 2008, serving as General Manager of Bioproduction Chromatography and Pharma Analytics before being named President of Bioproduction in 2011. From 2000 to 2008, Mr. Hunt was with Applied Biosystems as Senior Director of Pharma Programs where he launched the Pharma Analytics business that in 2008 became a part of the Bioproduction platform at Life Technologies. Mr. Hunt received a B.S. in Microbiology and an M.S. in Biotechnology from University College in Galway, Ireland, and an M.B.A. from Boston University School of Management. Mr. Hunt brings to the Board of Directors his deep understanding of the bioprocessing market.
As the President, Chief Executive Officer és Director of Repligen, the total compensation of Anthony Hunt at Repligen is $4,424,560. There are no executives at Repligen getting paid more.
Anthony Hunt is 56, he's been the President, Chief Executive Officer és Director of Repligen since 2015. There are 7 older and 4 younger executives at Repligen. The oldest executive at Repligen Corp. is Thomas Ryan, 78, who is the Independent Director.
Anthony's mailing address filed with the SEC is C/O REPLIGEN CORPORATION, 41 SEYON ST., BLDG 1, STE 100, WALTHAM, MA, 02453.
Over the last 22 years, insiders at Repligen have traded over $118,224,292 worth of Repligen stock and bought 160,440 units worth $1,459,521 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Glenn P Muir és Walter C Herlihy. On average, Repligen executives and independent directors trade stock every 33 days with the average trade being worth of $3,015,702. The most recent stock trade was executed by Ralf Kuriyel on 2 August 2024, trading 7,148 units of RGEN stock currently worth $1,139,034.
repligen corporation is a life sciences company focused on the development, production and commercialization of products used in the process of manufacturing biological drugs. our bioprocessing products are sold to major life sciences and biopharmaceutical companies worldwide. we are a leading manufacturer of protein a, a critical reagent used to manufacture monoclonal antibody-based therapeutics. we also supply several growth factor products used to increase cell culture productivity in biomanufacturing. in the burgeoning area of disposable biomanufacturing technologies, we have developed and market a series of opus™ (open platform user specified) single-use chromatography columns used in the biologics purification process. repligen’s corporate headquarters are located in waltham, ma, usa; we have an additional manufacturing facility in lund, sweden.
Repligen executives and other stock owners filed with the SEC include: